[ad_1] Jazz Pharmaceuticals (NASDAQ: JAZZ) 2.9% falls in after-hours trading after reporting results of a late-stage trial of liposome Vyxeos for injections in two kinds of blood cancer. The study 309 patients …
Read More »[ad_1] Jazz Pharmaceuticals (NASDAQ: JAZZ) 2.9% falls in after-hours trading after reporting results of a late-stage trial of liposome Vyxeos for injections in two kinds of blood cancer. The study 309 patients …
Read More »